NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
Clinical Trials
41 trialsNCT04190446 2026-03-16
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT03269422 2025-09-30
Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02177292 2025-07-01
SIB
Medical College of Wisconsin
Phase NA Active not recruiting
NCT06546267 2025-06-11
PROST-ART
IRCCS San Raffaele
Recruiting
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT06971211 2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2 Recruiting
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT05523856 2025-03-12
TTOPROST/OBS
Fundacion IMIM
Active not recruiting
NCT01985828 2024-10-03
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Wake Forest University Health Sciences
Phase NA Completed
NCT00321698 2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT01802242 2024-03-18
Tumor TARGET Prostate Cancer
University Health Network, Toronto
Phase NA Active not recruiting
NCT02279693 2024-02-14
PROSTRACK
Centre Georges Francois Leclerc
Phase NA Terminated
NCT03241537 2023-11-27
COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
Samsung Medical Center
Phase 3 Active not recruiting
NCT00482807 2023-11-24
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Phase 1 Completed
NCT03553212 2023-05-30
THRIP
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase NA Terminated
NCT00951535 2023-04-06
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Unknown
NCT01968538 2023-02-28
Metabolomic Study for Localized Prostate Cancer
Georgetown University
Unknown
NCT01618851 2023-02-22
Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
Georgetown University
Phase NA Unknown
NCT00033631 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02064036 2022-10-18
CCRO025
University of California, Davis
Phase 1 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02508636 2021-10-12
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01325961 2021-05-24
RCMI PELVIS
Institut Cancerologie de l'Ouest
Phase NA Completed
NCT02805894 2021-05-10
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
Nanobiotix
Phase 1/2 Terminated
NCT01764646 2020-05-19
Hypofractionated Radiation Therapy in Prostate Cancer
University Hospital, Geneva
Phase NA Unknown
NCT00714753 2019-08-07
Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT01028885 2019-07-25
MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01654068 2019-04-19
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
University of Kentucky
Phase NA Terminated
NCT02546427 2018-02-12
Hypofractionated Whole Pelvic Radiotherapy of the Prostate
University of California, San Francisco
Phase NA Withdrawn
NCT00551525 2017-07-25
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02974231 2016-11-28
Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer
Institut de Cancérologie de Lorraine
Completed
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT00126802 2016-07-06
The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer
AHS Cancer Control Alberta
Phase 1/2 Unknown
NCT01603420 2016-03-14
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
Phase 2/3 Terminated
NCT00452556 2014-03-19
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
Nova Scotia Cancer Centre
Phase 2 Unknown
NCT00946543 2013-08-26
Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Unknown